Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Progenics Pharma (PGNX) Reports Completion of Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404January 2, 2018 8:30 AM Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and ParagangliomaDecember 29, 2017 8:30 AM